Dr Steve Thorne | Chief Scientific Officer
Western Oncolytics

Dr Steve Thorne, Chief Scientific Officer, Western Oncolytics

Assistant Professor, Department of Cell Biology and Department of Immunology, University of Pittsburgh, University of Pittsburgh Cancer Institute, Pittsburgh, PA, Chief Scientific Officer, Western Oncolytics Ltd
 
Dr. Thorne has many years experience working with different oncolytic vaccinia and related viruses. This includes design, engineering, pre-clinical testing, translational development and IND-enabling and early phase clinical testing. He has pioneered the use of these vectors alone, notably as immunotherapies and in combination with immune cell-based and antibody-based therapies. Dr. Thorne’s Undergraduate degree was obtained from Oxford University and his Ph.D. from Imperial College in London, with post-doctoral experience at Cancer Research UK and Stanford University. He has been faculty at The University of Pittsburgh for 8 years and has over 80 publications in refereed journals (including Science, Nat Med, JCI, PLoS Medicine, PNAS USA, Can Cell, Can Res, Cell Host Microbe and Nat Rev Can). In addition he has been involved with several Biotech start-ups, including Jennerex Biotherapuetics (now a part of Sillajen), and more recently Western Onclytics Ltd.  He is currently taking an entrepreneurial leave of absence from the University of Pittsburgh to act as CSO at Western Oncolytics.

Appearances:



Agenda Day 1 @ 5:00

Delivering multiple immunotherapies in a single construct; what makes WO-12 unique amongst oncolytic virotherapies?

  • WO-12 is an immuno-oncolytic virus engineered to replicate in cancer cells while delivering therapeutic transgenes that train the immune system to target the tumor
  • How does WO-12's interaction with TLR signalling pathways result in increased beneficial T-Cell responses while reducing the antibody response?
  • The importance of modifying the tumour micro-environment in eliciting good immunotherapeutic responses
  • Challenges to overcome in achieving systemic delivery
  • Outlook for beginning of human clinical trials in 2018

back to speakers